EMA Authorised: Prevenar 13 (Pneumococcal polysaccharide serotype 1;Pneumococcal polysaccharide serotype 3;Pneumococcal polysaccharide serotype 4;Pneumococcal polysaccharide serotype 5;Pneumococcal polysaccharide serotype 6A;Pneumococcal polysaccharide serotype 6B;Pneumococcal polysaccharide serotype 7F;Pneumococcal polysaccharide serotype 9V;Pneumococcal polysaccharide serotype 14;Pneumococcal polysaccharide serotype 18C;Pneumococcal polysaccharide serotype 19A;Pneumococcal polysaccharide serotype 19F;Pneumococcal polysaccharide serotype 23F) — Pfizer Europe MA EEIG

View source ↗

Summary

EMA authorised Prevenar 13, a 13-valent pneumococcal conjugate vaccine, for immunization against pneumococcal infections in the EU. The vaccine covers serotypes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Pneumococcal Disease
• Otitis Media
• Pneumonia

Drugs mentioned

• Prevenar 13 (Pneumococcal conjugate vaccine (13-valent))

Snippet

Status: Authorised. Therapeutic area: Pneumococcal Infections;Immunization. MAH: Pfizer Europe MA EEIG. Decision date: 15/01/2026